Cardiac arrest from acquired long QT syndrome: A case report

LaPointe, 2006, Frequency of high-risk use of QT-prolonging medications, Pharmacoepidemiol Drug Saf, 15, 361, 10.1002/pds.1155

Kunkler, 2002, Acquired long QT syndrome: risk assessment, prudent prescribing and monitoring, and patient education, J Am Acad Nurse Pract, 14, 382, 10.1111/j.1745-7599.2002.tb00139.x

Justo, 2006, Torsades de pointes induced by antibiotics, Eur J Intern Med, 17, 254, 10.1016/j.ejim.2005.12.003

Aslam, 2006, Hypothermia: evaluation, electrocardiographic manifestations, and management, Am J Med, 119, 297, 10.1016/j.amjmed.2005.09.062

Al-Khatib, 2003, What clinicians should know about the QT interval, JAMA, 289, 2120, 10.1001/jama.289.16.2120

Lankipalli, 2005, Mechanisms underlying arrhythmogenesis in long QT syndrome, J Electrocardiol, 38, 69, 10.1016/j.jelectrocard.2005.06.008

Cubeddu, 2003, QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs, Am J Ther, 106, 452, 10.1097/00045391-200311000-00013

Owens, 2004, QT prolongation with antimicrobial agents, Drugs, 64, 1091, 10.2165/00003495-200464100-00005

Tisdale, 2007, Accuracy of uncorrected versus corrected QT interval for prediction of torsades de pointes associated with intravenous haloperidol, Pharmacotherapy, 27, 175, 10.1592/phco.27.2.175

Milne, 1982, The ventricular paced QT interval—the effects of rate and exercise, Pacing Clin Electrophysiol, 5, 352, 10.1111/j.1540-8159.1982.tb02242.x

Moss, 2001, ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary, Ann Noninvasive Electrocardiol, 6, 333, 10.1111/j.1542-474X.2001.tb00127.x

Darpo, 2006, Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use E14 Guideline, J Clin Pharmacol, 46, 498, 10.1177/0091270006286436

Darpo, 2006, Man versus machine: is there an optimal method for QT measurements in thorough QT studies?, J Clin Pharmacol, 46, 598, 10.1177/0091270006286900

Curtis, 2003, Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients, Am J Med, 114, 135, 10.1016/S0002-9343(02)01455-9

Thomas, 2002, The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels, J Pharmacol Exp Ther, 300, 543, 10.1124/jpet.300.2.543

Winkler, 2006, Trazodone-induced cardiac arrhythmias: a report of two cases, Hum Psychopharmacol, 21, 61, 10.1002/hup.746

Rajamani, 2006, Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine, Br J Pharmacol, 149, 481, 10.1038/sj.bjp.0706892

Pacher, 2004, Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?, Curr Pharm Des, 10, 2463, 10.2174/1381612043383872

Park, 1999, Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes, Yonsei Med J, 40, 144, 10.3349/ymj.1999.40.2.144

Roden, 2005, Genetics of acquired long QT syndrome, J Clin Invest, 115, 2025, 10.1172/JCI25539

Drew, 2004, Practice standards for electrocardiographic monitoring in hospital settings, Circulation, 110, 2721, 10.1161/01.CIR.0000145144.56673.59

Drew, 2006, Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation, Crit Care Nurs Clin N Am, 18, 157, 10.1016/j.ccell.2006.01.007

Viskin, 1999, Long QT syndromes and torsades de pointes, Lancet, 354, 1625, 10.1016/S0140-6736(99)02107-8

Vincent, 2001, Prevention of drug-induced long QT syndrome: gender, chemistry, and education, J Cardiovasc Electrophysiol, 12, 546, 10.1046/j.1540-8167.2001.00546.x